BACKGROUND: Recently, two functional IL18 promoter variants, -607C>A (rs1946518) and -137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response. METHODS: Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%. RESULTS: Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p = 0.0416 and p = 0.0274, respectively). In viral genotype 1, the -607A allele was positively associated with treatment response (p = 0.0190; OR 1.537; 95% CI, 1.072-2.205) and the -137G allele with a higher rate of nonresponse (p = 0.0302; OR 1.524; 95% CI, 1.040-2.233). CONCLUSIONS: The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.
BACKGROUND: Recently, two functional IL18 promoter variants, -607C>A (rs1946518) and -137G>C (rs187238), were associated with viral clearance in patients with hepatitis C. The present study focused on their relevance for treatment response. METHODS: Seven hundred fifty-seven chronically infected European patients and 791 controls were enrolled in the study. IL18 genotyping was performed by allele-specific PCR. Liver histology was available in 67.9%. RESULTS: Genotype and allele frequencies were equally distributed in patients and controls. No significant association with various disease characteristics was observed. However, when comparing patients with sustained virological response (SR) and non-SR, statistically significant associations were found for both variants (p = 0.0416 and p = 0.0274, respectively). In viral genotype 1, the -607A allele was positively associated with treatment response (p = 0.0190; OR 1.537; 95% CI, 1.072-2.205) and the -137G allele with a higher rate of nonresponse (p = 0.0302; OR 1.524; 95% CI, 1.040-2.233). CONCLUSIONS: The association of IL18 variants with treatment response in genotype 1 hepatitis C patients implies a predictive and modifying role of these genetic variants.
Authors: T K Oleksyk; C L Thio; A L Truelove; J J Goedert; S M Donfield; G D Kirk; D L Thomas; S J O'Brien; M W Smith Journal: Genes Immun Date: 2005-06 Impact factor: 2.676
Authors: R Faggioni; R C Cattley; J Guo; S Flores; H Brown; M Qi; S Yin; D Hill; S Scully; C Chen; D Brankow; J Lewis; C Baikalov; H Yamane; T Meng; F Martin; S Hu; T Boone; G Senaldi Journal: J Immunol Date: 2001-11-15 Impact factor: 5.422
Authors: Andrew R Lloyd; Emma Jagger; Jeffrey J Post; Lee-Ann Crooks; William D Rawlinson; Young S Hahn; Rosemary A Ffrench Journal: Immunol Cell Biol Date: 2006-11-28 Impact factor: 5.126
Authors: Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Richard B Kennedy; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland Journal: J Infect Dis Date: 2011-08-01 Impact factor: 5.226
Authors: Asmaa M Abdel-Aziz; Mohamed A Ibrahim; Azza A El-Sheikh; Maha Y Kamel; Nagwa M Zenhom; Salam Abdel-Raheim; Hisham Abdelhaleem Journal: J Clin Exp Hepatol Date: 2017-06-30
Authors: Isabel Pérez-Flores; Jose Luis Santiago; Cristina Fernández-Pérez; Elena Urcelay; María Ángeles Moreno de la Higuera; Natividad Calvo Romero; Beatriz Rodríguez Cubillo; Ana Isabel Sánchez-Fructuoso Journal: Open Forum Infect Dis Date: 2019-07-20 Impact factor: 3.835
Authors: Paula Keiko Sato; Felipe Delatorre Busser; Flávia Mendes da Cunha Carvalho; Alexandra Gomes Dos Santos; Aya Sadahiro; Constancia Lima Diogo; Adriana Satie Gonçalves Kono; Maria Luiza Moretti; Olinda do Carmo Luiz; Maria Aparecida Shikanai-Yasuda Journal: Front Immunol Date: 2020-10-01 Impact factor: 7.561